TD Cowen analyst Joseph Thome maintained a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report) yesterday and set a price target of $205.00.
Joseph Thome has given his Buy rating due to a combination of factors including Jazz Pharmaceuticals’ solid growth prospects and strategic positioning. Despite a slight underperformance in Q1 revenue, largely due to seasonal and competitive pressures, the company has shown resilience with an increase in Xywav patient numbers, which is a key growth driver.
Furthermore, Jazz Pharmaceuticals has reaffirmed its full-year 2025 revenue guidance, projecting between $4.15-4.4 billion, and has assured that tariffs will not materially impact its business. The anticipation of pivotal Phase III data for Ziihera in GEA later this year is also a significant catalyst, with expectations of positive outcomes potentially driving substantial upside in share value. These factors collectively underpin Thome’s optimistic outlook on Jazz Pharmaceuticals’ stock.
In another report released on April 28, RBC Capital also maintained a Buy rating on the stock with a $182.00 price target.
Based on the recent corporate insider activity of 63 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of JAZZ in relation to earlier this year.